Evidence map›Paper›PMID 34807763›Full record

Trial reportAntimicrobial agents and chemotherapy2022

Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B.

Chia-Ming Lu, Jin-Shiung Cheng, Wei-Chih Sun, Wen-Chi Chen, Feng-Woei Tsay, Huay-Min Wang, Tzung-Jiun Tsai, Sung-Shuo Kao, Yun-Da Li, Yuan-Rong Li and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Chia-Ming LuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Jin-Shiung ChengDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Wei-Chih SunDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Wen-Chi ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Feng-Woei TsayDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Huay-Min WangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Tzung-Jiun TsaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Sung-Shuo KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Yun-Da LiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Yuan-Rong LiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Huey-Shyan LinSchool of Nursing, Fooyin University, Kaohsiung, Taiwan.
Chun-Hao YinDepartment of Medical Education and Research, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.
Wei-Lun TsaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospitalgrid.415011.0, Kaohsiung, Taiwan.ORCID 0000-0001-7557-3370
National Yang Ming Chiao Tung University · TWFooyin University · TWKaohsiung Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spontaneous severe acute exacerbation (SAE) is not uncommon in the natural history of chronic hepatitis B (CHB). Lamivudine (LAM) has the advantages of low price, quick onset, good efficacy, and no drug resistance within 24 weeks. This study aimed to compare the short-term efficacy of tenofovir disoproxil fumarate (TDF) and LAM for 24 weeks followed by TDF in the treatment of CHB with severe acute exacerbation. Consecutive patients of CHB with SAE were randomized to receive either TDF (19 patients) or LAM for 24 weeks, followed by TDF (18 patients). The primary endpoint was overall mortality or receipt of liver transplantation by week 24. This study was approved by the Institutional Review Board (IRB) of the Kaohsiung Veterans General Hospital (VGHKS12-CT5-10). The baseline characteristics were comparable between the two groups. By week 24, seven (37%) and five (28%) patients in the TDF and LAM-TDF groups died or received liver transplantation (

Indexed as

Hepatitis BHepatitis B, ChronicAntiviral AgentsDNA, ViralDrug Resistance, ViralDrug Therapy, CombinationHepatitis B virusHumansLamivudineTenofovirTreatment OutcomeAntiviral AgentsDNA, ViralLamivudineTenofoviracute exacerbationexacerbationhepatitis B viruslamivudinetenofovir disoproxil fumarate

Identifiers

PMID34807763
PMCPMC8846303
OpenAlexW3215953183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.